Nordson (NDSN) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
8 Jul, 2026Executive summary
Achieved record FY2024 sales of $2.7 billion and record EBITDA of $849 million (32% of sales), driven by the Ascend Strategy, NBS Next Growth Framework, and acquisitions, despite macroeconomic and supply chain challenges.
Fourth quarter sales reached $744 million, up 4% year-over-year, with adjusted EPS of $2.78 and successful integration of the Atrion acquisition.
Demonstrated strong cash flow and consistent performance, with free cash flow of $492 million (105% conversion rate).
Entered FY2025 with a $580 million backlog and a conservative outlook due to macroeconomic uncertainties.
High recurring revenue (57% of total) and diversified end markets supported resilience.
Financial highlights
Fiscal 2024 sales reached $2.7 billion, up 2% year-over-year, with acquisitions contributing 5% growth.
Record EBITDA of $849 million, up 4% year-over-year, with EBITDA margin at 32%.
Q4 adjusted operating profit was $205 million, with Q4 EBITDA at $241 million (32% of sales), up 6% year-over-year.
FY2024 adjusted EPS was $9.73, down 1% year-over-year due to higher interest costs from acquisitions; GAAP EPS was $8.11.
Free cash flow for the year was $492 million (105% conversion), with cash balances at $116 million and net debt at $2.1 billion (2.5x leverage).
Outlook and guidance
FY2025 sales expected to grow 2%-7% over FY2024, with adjusted EPS guidance of $9.70–$10.50 (flat to up 8%).
Guidance assumes 6% growth from the Atrion acquisition, -1.5% FX impact, and no significant recovery in electronics or agriculture.
Q1 FY2025 sales forecasted at $615M–$655M, with adjusted EPS of $1.95–$2.15.
Effective tax rate expected at 19%-21%, capex at $50M–$60M, and interest expense at $90M–$100M.
Management remains cautious on end market recovery timing, especially in electronics and agriculture.
Latest events from Nordson
- Sales fell 2.8–3% but backlog surged 15%, signaling growth potential for 2025.NDSN
Q1 20259 Jul 2026 - Q3 sales up 2% to $662M; Atrion acquisition expands portfolio; full-year guidance raised.NDSN
Q3 20249 Jul 2026 - Record sales, raised guidance, and strong cash flow reflect broad-based growth and demand.NDSN
Q2 202621 May 2026 - Sales up 12%, adjusted EPS up 13%, record cash flow, and FY25 guidance reaffirmed.NDSN
Q3 202521 May 2026 - Sustained growth, high margins, and strong 2026 outlook driven by innovation and disciplined strategy.NDSN
Investor presentation21 May 2026 - Record sales and net income, with raised guidance and strong growth in ATS and Asia Pacific.NDSN
Q1 20268 Apr 2026 - Q1 2026 sales rose 9% with raised full-year outlook and strong cash flow conversion.NDSN
Investor presentation26 Mar 2026 - Strong growth, innovation, and cash flow support 6-8% annual revenue growth through 2029.NDSN
Investor presentation19 Feb 2026 - 2025–2029 targets 6%-8% revenue and 10%-12% EPS growth, driven by strategy and portfolio evolution.NDSN
Investor Day 202420 Jan 2026